Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological diagnosis of pancreatic carcinoma
Patients ≥ 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status 0,1,or 2
Patients must have distant metastatic disease (stage 4)
Satisfactory organ and bone marrow function as defined by: Absolute neutrophil count\> 1,000/uL, Platelets \> 75,000uL Hemoglobin \> 9 Bilirubin ≤ 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor,
Creatinine ≤ 1.5x the institutional normal upper limit
Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5x the institutional normal upper limit.
A clinical recommendation for radiotherapy to the primary or a metastatic lesion had been made.
Must be able to provide informed consent.
You may not be if
No prior radiation to the area planned for radiotherapy
Active invasive cancer other than pancreatic adenocarcinoma. Non-melanoma skin cancer, superficial cervical or bladder cancer and prostate cancer with PSA level \< 1.0 are not excluded.
Known HIV, HCV and/or HBV positive (by patient report/medical record)
Patients with ongoing or active infection
Planned concurrent treatment with systemic high dose corticosteroids.
Received an anticancer treatment (systemic therapy or radiation therapy)within 21 days prior to enrollment.
Immunotherapy (e.g. monoclonal antibodies)within 21 days prior to enrollment.
Immunosuppressive therapies (e.g. steroids, cyclosporine) are not permitted.
Clareo Health | A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas
